Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases

被引：43

作者：

McBride, Christopher M. ^{[1
]}

Renhowe, Paul A. ^{[1
]}

Heise, Carla ^{[1
]}

Jansen, Johanna M. ^{[1
]}

Lapointe, Gena ^{[1
]}

Ma, Sylvia ^{[1
]}

Pineda, Ramon ^{[1
]}

Vora, Jayesh ^{[1
]}

Wiesmann, Marion ^{[1
]}

Shafer, Cynthia M. ^{[1
]}

机构：

[1] Chiron Corp, Biopharma Div, Small Mol Drug Discovery, Emeryville, CA 94608 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 13期

关键词：

indazole benzimidazole; receptor tyrosine kinase (RTK); vascular endothelial growth factor (VEGF); basic fibroblast growth factor (bFGF); platelet derived growth factor (PDGF);

D O I：

10.1016/j.bmcl.2006.03.069

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：3595 / 3599

页数：5

共 14 条

[11] Tumor angiogenesis: past, present and the near future [J].

Kerbel, RS .

CARCINOGENESIS, 2000, 21 (03) :505-515

[12] Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain [J].

Mohammadi, M ;

Froum, S ;

Hamby, JM ;

Schroeder, MC ;

Panek, RL ;

Lu, GH ;

Eliseenkova, AV ;

Green, D ;

Schlessinger, J ;

Hubbard, SR .

EMBO JOURNAL, 1998, 17 (20) :5896-5904

[13]

*PFIZ INC, 2006, FDA APPR PFIZ SUT KI

[14]

SHAFER CM, 2004, 228 ACS NAT M PHIL P

← 1 2 →